Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.

ABSTRACT:

Objective

To predict long-term disability outcomes in TEMSO core (NCT00134563) and extension (NCT00803049) studies in patients with relapsing forms of MS treated with teriflunomide.

Methods

A post hoc analysis was conducted in a subgroup of patients who received teriflunomide in the core study, had MRI and clinical relapse assessments at months 12 (n = 552) and 18, and entered the extension. Patients were allocated risk scores for disability worsening (DW) after 1 year of teriflunomide treatment: 0 = low risk; 1 = intermediate risk; and 2-3 = high risk, based on the occurrence of relapses (0 to ≥2) and/or active (new and enlarging) T₂-weighted (T₂w) lesions (≤3 or >3) after the 1-year MRI. Patients in the intermediate-risk group were reclassified as res

SUBMITTER: Sormani MP 

PROVIDER: S-EPMC5489388 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature